Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: RJMC who wrote (3672)	11/7/2000 12:05:40 AM
From: Gary Mohilner	Respond to of 5665

Bob, I and others on R.B. have exchanged several messages with Biocoach, I find him to be well informed. I'd suggest going over there and reading those messages. In one of them he indicates that he expects additional data and information will be added in the final presentation. My belief is in the abstract they wanted to call everyones attention to Pancreatic Cancer, because their's nothing that's effective against it. In the actual presentation I believe they'll say more about Pancreatic Cancer, but I believe they'll be talking about the results with refractory Colon Cancer patients as well. The results for both cancers had to be good, or they wouldn't have started the Multi Dose Trial on both of them. I believe they're still getting data for non small cell Lung Cancer in the Single Dose Trial before they decide to take it into Multi Dose or not. Gary